Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
24 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
Current reports
8-K
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
15 Apr 24
8-K
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
27 Mar 24
8-K
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
5 Mar 24
8-K
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
4 Jan 24
8-K
Other Events
28 Nov 23
8-K
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Other Events
28 Sep 23
8-K
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
19 Sep 23
8-K
Other Events
21 Aug 23
8-K
Other Events
15 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
28 Jun 23
S-3
Shelf registration
31 Mar 23
424B5
Prospectus supplement for primary offering
9 Nov 22
424B5
Prospectus supplement for primary offering
7 Nov 22
S-8
Registration of securities for employees
27 Jun 22
D
$1.23M in equity, sold $1.23M, 1 investor
4 Apr 22
S-8
Registration of securities for employees
10 Aug 21
424B5
Prospectus supplement for primary offering
9 Dec 20
424B5
Prospectus supplement for primary offering
7 Dec 20
S-8
Registration of securities for employees
10 Jul 20
Proxies
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
DEFA14A
Additional proxy soliciting materials
11 Apr 22
DEF 14A
Definitive proxy
11 Apr 22
DEFA14A
Additional proxy soliciting materials
15 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
DEF 14A
Definitive proxy
27 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
Other
EFFECT
Notice of effectiveness
12 Apr 23
CORRESP
Correspondence with SEC
11 Apr 23
UPLOAD
Letter from SEC
5 Apr 23
EFFECT
Notice of effectiveness
28 Jul 20
CORRESP
Correspondence with SEC
24 Jul 20
CORRESP
Correspondence with SEC
20 Jul 20
UPLOAD
Letter from SEC
16 Jul 20
CORRESP
Correspondence with SEC
16 Jul 20
EFFECT
Notice of effectiveness
15 May 20
CORRESP
Correspondence with SEC
13 May 20
Ownership
SC 13G
TANG CAPITAL PARTNERS LP
19 Apr 24
4
Scott Braunstein
27 Mar 24
4
Christina Shafer
22 Feb 24
4
MARTHA E MANNING
22 Feb 24
4
Joseph Hulihan
21 Feb 24
4
Steven Pfanstiel
21 Feb 24
4
Scott Braunstein
21 Feb 24
SC 13G/A
Lion Point Capital, LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24